PUK20 A COST EFFECTIVENESS ANALYSIS OF SOLIFENACIN COMPARED WITH EXTENDED-RELEASE TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER

PUK2 COST-EFFECTIVENESS ANALYSIS OF EXTENDED-RELEASE TOLTERODINE VERSUS IMMEDIATE-RELEASE TOLTERODINE IN THE MANAGEMENT OF OVERACTIVE BLADDER IN SPAIN

Value in Health ◽

10.1016/s1098-3015(10)66140-2 ◽

2004 ◽

Vol 7 (6) ◽

pp. 798

Author(s):

D Castro ◽

J Soto ◽

I Exposito

Keyword(s):

Cost Effectiveness ◽

Overactive Bladder ◽

Extended Release ◽

Immediate Release ◽

PUK14 Cost-Effectiveness Analysis of Mirabegron Versus Tolterodine Extended Release in the Treatment of Patients With Overactive Bladder in the United States

Value in Health ◽

10.1016/j.jval.2012.08.1452 ◽

2012 ◽

Vol 15 (7) ◽

pp. A457

Author(s):

J. Xie ◽

Z.Y. Zhou ◽

C.N. Bui ◽

Y. Yan ◽

G. De ◽

...

Keyword(s):

United States ◽

Cost Effectiveness ◽

Overactive Bladder ◽

Extended Release ◽

The United States ◽

A Cost-Effectiveness Analysis of Guanfacine Extended-Release Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder

Value in Health ◽

10.1016/j.jval.2016.08.529 ◽

2016 ◽

Vol 19 (7) ◽

pp. A841

Author(s):

S Maeda ◽

K Shimozuma ◽

Y Takeda

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Cost Effectiveness ◽

Attention Deficit ◽

Extended Release ◽

Hyperactivity Disorder ◽

Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder

International Urogynecology Journal ◽

10.1007/s00192-018-3662-y ◽

2018 ◽

Vol 29 (8) ◽

pp. 1221-1221

Author(s):

Abdelmageed Abdelrahman

Keyword(s):

Cost Effectiveness ◽

Overactive Bladder ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Onabotulinumtoxin A ◽

First Line Treatment

Re: Cost-Effectiveness Analysis of Sacral Neuromodulation and Botulinum Toxin A Treatment for Patients With Idiopathic Overactive Bladder

The Journal of Urology ◽

10.1016/j.juro.2012.02.2534 ◽

2012 ◽

Vol 187 (6) ◽

pp. 2157-2158

Author(s):

David F. Penson

Keyword(s):

Botulinum Toxin ◽

Cost Effectiveness ◽

Overactive Bladder ◽

Sacral Neuromodulation ◽

Botulinum Toxin A ◽

Toxin A ◽

Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom

Journal of Medical Economics ◽

10.3111/13696998.2013.829079 ◽

2013 ◽

Vol 16 (10) ◽

pp. 1246-1254 ◽

Cited By ~ 6

Author(s):

Warren Mark Hart ◽

Paul Abrams ◽

Vicki Munro ◽

Peny Retsa ◽

Jameel Nazir

Keyword(s):

United Kingdom ◽

Cost Effectiveness ◽

Overactive Bladder ◽

Immediate Release ◽

The United Kingdom ◽

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model

BMC Urology ◽

10.1186/1471-2490-11-9 ◽

2011 ◽

Vol 11 (1) ◽

Cited By ~ 23

Author(s):

Salvador Arlandis-Guzman ◽

Carlos Errando-Smet ◽

Jeffrey Trocio ◽

Daniel Arumi ◽

Javier Rejas

Keyword(s):

Cost Effectiveness ◽

Overactive Bladder ◽

Decision Tree ◽

Decision Tree Model ◽

Tree Model ◽

PCV33: COST-EFFECTIVENESS ANALYSIS OF SIMVASTATIN AND LOVASTATIN/EXTENDED-RELEASE NIACIN TO ACHIEVE LDLAND HDL GOAL USING NHANES DATA

Value in Health ◽

10.1016/s1098-3015(10)64147-2 ◽

2003 ◽

Vol 6 (3) ◽

pp. 319

Author(s):

EP Armstrong ◽

WM Zachry ◽

DC Malone

Keyword(s):

Cost Effectiveness ◽

Extended Release ◽

Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s111646 ◽

2016 ◽

Vol Volume 8 ◽

pp. 541-550 ◽

Cited By ~ 1

Author(s):

Carmen Peral ◽

Francisco Sanchez-Ballester ◽

Jose Maria Garcia-Mediero ◽

Jaime Ramos ◽

Javier Rejas

Keyword(s):

Clinical Practice ◽

Cost Effectiveness ◽

Overactive Bladder ◽

Routine Clinical Practice ◽

Newly Diagnosed ◽

Effectiveness Analysis ◽

Flexible Dose

OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales

The European Journal of Health Economics ◽

10.1007/s10198-015-0737-2 ◽

2015 ◽

Vol 17 (7) ◽

pp. 911-921 ◽

Cited By ~ 6

Author(s):

Nick Freemantle ◽

Kristin Khalaf ◽

Clara Loveman ◽

Sanja Stanisic ◽

Dmitry Gultyaev ◽

...

Keyword(s):

Cost Effectiveness ◽

Overactive Bladder ◽

Supportive Care ◽

Best Supportive Care ◽

England And Wales ◽